Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma

CardioVascular and Interventional Radiology

Volumn 37, Issue 2, 2014, Pages 381-387

  Kalva, Sanjeeva P ^a   Pectasides, Melina ^b   Liu, Raymond ^b   Rachamreddy, Niranjan ^b   Surakanti, Shravani ^c   Yeddula, Kalpana ^d   Ganguli, Suvranu ^b   Wicky, Stephan ^b   Blaszkowsky, Lawrence S ^e   Zhu, Andrew X ^e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Baton Rouge General   (United States)

^d SAINT JOSEPH HOSPITAL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Cancer; Chemoembolization chemoembolisation; DEB TACE; Hepatocellular carcinoma; Interventional oncology; Liver hepatic

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DOXORUBICIN; DRUG CARRIER;

ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PATIENT; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; DEVICE SAFETY; DRUG DELIVERY DEVICE; DRUG ELUTING BEAD; FATIGUE; FEMALE; GROIN HEMATOMA; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOXIA; KIDNEY FAILURE; LEG EDEMA; LENGTH OF STAY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MIDDLE AGED; NAUSEA; OVERALL SURVIVAL; PAIN; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT RESPONSE; AGED; ANALYSIS OF VARIANCE; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FOLLOW UP; LIVER NEOPLASMS; MORTALITY; MULTIVARIATE ANALYSIS; PALLIATIVE THERAPY; PATHOLOGY; PATIENT SAFETY; PREDICTIVE VALUE; PROCEDURES; RISK ASSESSMENT; SURVIVAL; TIME; TREATMENT OUTCOME; TUMOR INVASION;

AGED; ANALYSIS OF VARIANCE; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG CARRIERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PALLIATIVE CARE; PATIENT SAFETY; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84897106579     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-013-0654-7     Document Type: Article

References (42)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108 (Pubitemid 40372904)
2. Marrero JA (2003) Hepatocellular carcinoma. Curr Opin Gastroenterol 19:243-249
3. Forner A, Reig ME, de Lope CR, Bruix J (2010) Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 30:61-74
4. Llovet JM (2005) Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 40:225-235
5. Bruix J, Sherman M (2005) Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 42:1208-1236
6. Bruix J, Sherman M (2011) American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 53:1020-1022
7. Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41-52
8. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
9. Faivre S, Raymond E, Boucher E et al (2009) Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 10: 794-800
10. Llovet JM, Real MI, Montaña X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734-1739 (Pubitemid 34607087)
11. Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164-1171 (Pubitemid 34454013)
12. Cammà C, Schepis F, Orlando A et al (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224:47-54 (Pubitemid 34680374)
13. Sakamoto I, Aso N, Nagaoki K et al (1998) Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics 18:605-619 (Pubitemid 128467047)
14. Chung JW, Park JH, Han JK et al (1996) Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 198:33-40
15. Solomon B, Soulen MC, Baum RA et al (1999) Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a US population. J Vasc Interv Radiol 10:793-798 (Pubitemid 29284310)
16. Malagari K, Pomoni M, Spyridopoulos TN et al (2011) Safety profile of sequential transcatheter chemoembolization with DC BeadTM: results of 237 hepatocellular carcinoma (HCC) patients. Cardiovasc Intervent Radiol 34:774-785
17. Malagari K, Alexopoulou E, Chatzimichail K et al (2008) Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imaging 33:512-519
18. Pomoni M, Malagari K, Moschouris H et al (2012) Postembolization syndrome in doxorubicin eluting chemoembolization with DC Bead. Hepatogastroenterology 59:820-825
19. Vogl TJ, Lammer J, Lencioni R et al (2011) Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. Am J Roentgenol 197:W562-W570
20. Carr BI, Bron K, Swanson DP (2011) Prospective randomized trial of hepatic artery chemotherapy with cisplatin and doxorubicin, with or without lipiodol in the treatment of advanced stage hepatocellular carcinoma. J Clin Gastroenterol 45:e87-e91
21. Watanabe S, Nishioka M, Ohta Y, Ogawa N, Ito S, Yamamoto Y (1994) Prospective and randomized controlled study of chemoembolization therapy in patients with advanced hepatocellular carcinoma. Cooperative Study Group for Liver Cancer Treatment in Shikoku area. Cancer Chemother Pharmacol 33(Suppl):S93-S96 (Pubitemid 24147974)
22. Lopez PM, Villanueva A, Llovet JM (2006) Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 23:1535-1547 (Pubitemid 43727460)
23. Trinchet JC, Ganne-Carrie N, Beaugrand M (2003) Review article: intra-arterial treatments in patients with hepatocellular carcinoma. Aliment Pharmacol Ther 17(Suppl 2):111-118 (Pubitemid 36831468)
24. Common terminology criteria for adverse events v3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm. Accessed 7 Apr 2012
25. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
26. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
27. Varela M, Sala M, Llovet JM, Bruix J (2003) Treatment of hepatocellular carcinoma: is there an optimal strategy? Cancer Treat Rev 29:99-104 (Pubitemid 36519391)
28. Venook AP (1994) Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 12:1323-1334
29. Maggs JR, Suddle AR, Aluvihare V, Heneghan MA (2012) Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma. Aliment Pharmacol Ther 35:1113-11134
30. Cormier JN, Thomas KT, Chari RS, Pinson CW (2006) Management of hepatocellular carcinoma. J Gastrointest Surg 10:761-780 (Pubitemid 43711147)
31. Choi JY (2011) Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea. Oncology 81(Suppl 1):141-147
32. Lencioni R, Chen XP, Dagher L, Venook AP (2010) Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist 15(Suppl 4):42-52
33. Oliveri RS, Wetterslev J, Gluud C (2011) Transarterial (chemo)-embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 3:CD004787
34. Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC (2001) Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol 12:321-326 (Pubitemid 32217030)
35. Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6-25 (Pubitemid 44900485)
36. van Malenstein H, Maleux G, Vandecaveye V et al (2011) A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 34:368-376
37. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS (2010) Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocellular carcinoma (HCC). J Surg Oncol 101:476-480
38. Nicolini A, Martinetti L, Crespi S, Maggioni M, Sangiovanni A (2010) Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 21:327-332
39. Llovet JM (2002) Evidence-based medicine in the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 17(Suppl 3):S428-S433
40. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF (2011) Phase II trial of Sorafenib combined with concurrent transarterial chemoembolization with drug eluting beads for hepatocellular carcinoma. J Clin Oncol 29:3960-3967
41. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, Camma C, Colombo M (2011) Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 54:2055-2063
42. Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, Konigberg R, Stauber R, Grunberger B, Muller C, Kolblinger C, Peck-Radosavljevic M, Sieghart W (2012) Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology 263:590-599